

MOL 12278

Intracellular K⁺ is required for the inactivation-induced high affinity binding of cisapride to HERG channels

Jijin Lin, Jun Guo, Hongying Gang, Peter Wojciechowski, Jeffrey T. Wagle, Shetuan Zhang

Institute of Cardiovascular Sciences, St. Boniface General Hospital Research Centre and
Department of Physiology (J.L., J.G., H.G., P.W., S.Z.), and Division of Stroke and Vascular
Disease, St. Boniface General Hospital Research Centre and Department of Biochemistry and
Medical Genetics (J.L., J.T.W.), Faculty of Medicine, University of Manitoba

MOL 12278

Intracellular K^+ modulation of cisapride block of HERG

Correspondence to: Shetuan Zhang, MD, Ph D

Institute of Cardiovascular Sciences, St. Boniface General Hospital Research

Centre and Department of Physiology, Faculty of Medicine

University of Manitoba

351 Tache Avenue, Winnipeg, Manitoba

Canada R2H 2A6

Tel: (204) 235-3455

Fax: (204) 233-6755

E-mail: szhang@sbr.ca

Total text pages: 26

Table: 2

Figures: 8

Total references: 30

Total words in abstract: 199

Total words in introduction: 581

Total words in discussion: 1265

Abbreviations:

HERG, human ether-a-go-go-related gene; I_{Kr} , cardiac rapidly activating delayed rectifier K^+ current; K^+_i , intracellular potassium concentration; K^+_o , extracellular potassium concentration.

MOL 12278

ABSTRACT

Many commonly used medications can cause long QT syndrome and thus increase the risk of life-threatening arrhythmias. High-affinity HERG (the Human Ether-a-go-go-Related Gene) potassium channel blockade by structurally diverse compounds is almost exclusively responsible for this side effect. Understanding drug-HERG channel interactions is an important step in avoiding drug-induced long QT syndromes. Previous studies have found that disrupting HERG inactivation reduces the degree of drug block and suggested that the inactivated state is the preferential state for drug binding to HERG channels. However, recent studies have also shown that inactivation does not dictate drug sensitivity of HERG channels. In the present study we have examined the effect of inactivation gating on cisapride block of HERG. Modulation of HERG inactivation was achieved by either changing extracellular K^+ or Cs^+ concentrations or by mutations of the channel. We found that while inactivation facilitated cisapride block of the HERG K^+ current, inactivation was not coupled with cisapride block of HERG when the Cs^+ current was recorded. Furthermore, cisapride block of the HERG K^+ current was not linked with inactivation in the mutant HERG channels F656V and F656M. Our results suggest that inactivation, through affecting the positioning of F656, facilitates cisapride block of HERG channels.

INTRODUCTION

The delayed rectifier potassium current (I_K) is the principal current responsible for cardiac repolarization and I_K is subdivided into the rapidly and slowly activating components, I_{Kr} and I_{Ks} , respectively (Sanguinetti and Jurkiewicz, 1990). The Human Ether-a-go-go-Related Gene, HERG, encodes the pore-forming subunit of the I_{Kr} channels (Sanguinetti *et al.*, 1995; Trudeau *et al.*, 1995). Reduction of I_{Kr} results in the prolongation of the cardiac action potential duration and causes the human long QT syndrome (LQTS) (Keating and Sanguinetti, 2001), a disorder of myocellular repolarization that predisposes affected individuals to life-threatening ventricular tachyarrhythmia and sudden cardiac death (Keating and Sanguinetti, 2001). While congenital LQTS is relatively rare, acquired LQTS is far more frequent and is a side effect of a variety of common medications. Theoretically, a reduction of any voltage-gated K^+ current that contributes to ventricular repolarization could cause LQTS. However, almost all known drugs that cause LQTS preferentially block the HERG channels (Roden *et al.*, 1996; Mitcheson *et al.*, 2000a). HERG blockade by different drugs represents one of the major concerns in drug safety. Thus, it is imperative to understand the molecular mechanisms that underlie drug-induced HERG channel block.

HERG displays a characteristic fast voltage dependent inactivation gating. When depolarized, HERG channels open at a rate slower than that of inactivation (Smith *et al.*, 1996; Spector *et al.*, 1996). Upon repolarization, inactivated channels quickly reopen and then deactivate. Hence, depolarized HERG channels primarily exist in either the open or the inactivated state (Smith *et al.*, 1996; Spector *et al.*, 1996). Previous studies have shown that for most HERG-blocking agents block develops only when the channel is depolarized (Snyders and Chaudhary, 1996; Kiehn *et al.*, 1996;

MOL 12278

Zhang *et al.*, 1999), suggesting that one or both of the depolarization-induced states (open vs. inactivated) represent high-affinity states for drug binding. It has been found that mutations of HERG that disrupt the inactivation reduce HERG block by E-4031, dofetilide and verapamil (Ficker *et al.*, 1998; Zhang *et al.*, 1999), suggesting that it is the inactivated state which forms the high affinity receptor for drug binding. However, a recent study suggested that the positioning of S6 aromatic residues relative to the central cavity of the channel, not inactivation *per se*, determines the drug block of HERG channels (Chen *et al.*, 2002).

It has been reported that the elevation of extracellular K^+ concentration (K^+_o) relieves drug block of I_{Kr} /HERG channels (Yang and Roden, 1996; Wang *et al.*, 1997). Because most HERG blockers access HERG channels from the cytosolic side of the membrane (Zhang *et al.*, 1999; Mitcheson *et al.*, 2000b; Zhang *et al.*, 2001), it is of interest to know whether intracellular K^+ concentration (K^+_i) regulates drug binding to HERG channels.

In the present study, we used a well studied HERG blocker cisapride (Mohammad *et al.*, 1997; Mitcheson *et al.*, 2000a; Chen *et al.*, 2002; Fernandez *et al.*, 2004) to investigate the molecular mechanisms of drug-HERG channel interactions. Whole cell patch clamp technique (Zhang *et al.*, 2003b) was used to record currents from the wild type (WT) and mutant HERG channels heterologously expressed in HEK 293 cells. By using Cs^+ permeation and site-directed mutations we have found that when intracellular K^+ was replaced by Cs^+ or when Phe-656 was mutated to Valine or Methionine, the cisapride block of HERG channels was no longer dependent on inactivation gating. We propose that inactivation re-orientates Phe-656 to a position that favors high

MOL 12278

affinity binding of cisapride to HERG channels, and the presence of intracellular K^+ is required for this process.

MOL 12278

MATERIALS AND METHODS

Molecular Biology

We made three mutations in the pore and S6 region to assess the role of inactivation in the cisapride block of HERG channels. The S620T mutation was made to remove HERG inactivation gating (Ficker *et al.*, 1998; Zhang *et al.*, 1999). The F656V and F656M mutations were made to modify cisapride binding to HERG. The F656V and F656M mutations were selected for two reasons. First, the Phe-656 residue of HERG has been shown to be a molecular determinant of high affinity dofetilide and cisapride binding (Lees-Miller *et al.*, 2000; Mitcheson *et al.*, 2000a). Second, these mutant channels have been shown to display properties which are similar to that of WT channels (Lees-Miller *et al.*, 2000; Fernandez *et al.*, 2004).

HERG cDNA in pCDNA3 was obtained from Dr. Gail A. Robertson (The University of Wisconsin (Trudeau *et al.*, 1995)). Point mutations in the P-loop and S6 of HERG were introduced via PCR using overlap extension (Ho *et al.*, 1989) (Table 1).

The forward and reverse flanking primers were designed to cover two unique restriction sites (*BstEII* at nucleotide 2038 and *SbfI* at nucleotide 3093). The first round of PCRs was performed using the forward flanking primer-reverse mutant primer and the reverse flanking primer-forward mutant primer. In the first round of PCRs, the total reaction volume was 50 μ l including 50 pmol of each primer, 70 ng of HERG cDNA, and 0.125 units of Vent DNA polymerase (New England Biolabs). Reaction temperatures were varied using a thermal cycler (MyCycler, Bio-Rad): 95°C, 120 s; 94°C, 60 s, 55°C, 60 s and 72°C, 60 s for 30 cycles; 72 °C, 10 min. The resulting PCR products were used as templates and amplified by flanking primers in a second round of PCR. The

MOL 12278

final PCR product was digested with *BstEII* and *SbfI* and ligated to HERG expression plasmid digested with the same two restriction enzyme sites.

All mutations were verified by using a high-throughput 48 capillary ABI 3730 sequencer (UCDNA Services, University of Calgary).

HERG S620T, F656V and F656M mutant channels were transiently expressed in HEK 293 cells (American Type Culture Collection, Rockville, MD). HEK 293 cells were seeded at 5×10^3 cells/60-mm diameter dish. The cells were transiently transfected using 10 μ l Lipofectamine with 4 μ g HERG mutant expression vector. After 24-48 h, at least 50% of cells expressed channels. Non-transfected HEK 293 cells contain a small-amplitude background current that is usually less than 100 pA upon a depolarizing pulse to 50 mV. Thus, the effects of overlapping endogenous currents of HEK 293 cells on the expressed current are minimal (Zhou *et al.*, 1998).

A HEK 293 cell line stably expressing HERG channels was obtained from Dr. Craig January's lab (The University of Wisconsin, (Zhou *et al.*, 1998)), where the HERG cDNA ((Trudeau *et al.*, 1995; Trudeau *et al.*, 1996)) was subcloned into *BamHI/EcoRI* sites of the pCDNA3 vector (Invitrogen). The stably transfected cells were cultured in Minimum Essential Medium (MEM) supplemented with 10% fetal bovine serum and contained 400 μ g/ml G418 to select for transfected cells.

For electrophysiological study, the cells were harvested from the culture dish by trypsinization, and stored in standard MEM medium at room temperature for later use. Cells were studied within 8 h of harvest.

Patch Clamp Recording Method

MOL 12278

The whole cell patch clamp method was used. The pipette solution contained 135 mM KCl or CsCl, 5 mM EGTA, 1 mM MgCl₂, 10 mM HEPES, and was adjusted to pH 7.2 with KOH or CsOH. The bath solution contained 10 mM HEPES, 10 mM glucose, 1 mM MgCl₂, 2 mM CaCl₂, 135 mM NaCl, and was adjusted to pH 7.4 with NaOH. For recordings in the presence of different external K⁺ or Cs⁺ concentrations, the concentration of Na⁺ was reduced as the K⁺ or Cs⁺ concentration was elevated to maintain a constant osmolarity, and the pH was adjusted to 7.4 with the appropriate hydroxide solution. All chemicals were from Sigma. Throughout the text the subscripts *i* and *o* denote, respectively, intra- and extra-cellular ion concentrations.

Aliquots of cells were allowed to settle on the bottom of a <0.5 mL cell bath mounted on an inverted microscope (TE2000, Nikon). Cells were superfused with specific bath solutions. The bath solution was constantly flowing through the chamber and the solution was changed by switching the perfusates at the inlet of the chamber. This bath solution change took 10 s. Patch electrodes were fabricated using thin-walled borosilicate glass (World Precision Instruments; FL, USA). The pipette had inner diameters of ~1.5 μm and had resistances of ~2 MΩ when filled with the pipette solution. An Axopatch 200B amplifier was used to record membrane currents. Computer software (pCLAMP9, Axon Instruments, Foster City, CA) was used to generate voltage clamp protocols, acquire data, and analyze current signals. Data were filtered at 5-10 kHz and sampled at 20-50 kHz for all protocols. Typically, 80% series resistance (R_s) compensation was used and leak subtraction was not used. Conductance/voltage data were fitted to a single Boltzmann function, $y = 1 / (1 + \text{Exp}((V_{1/2} - V)/k))$, where *y* is the current normalized with respect to the maximal tail current, V_{1/2} is the half-activation potential or mid-point of the activation curve, *V* is the voltage during the pre-pulse and *k* is the slope factor, in mV, reflecting the steepness of the voltage dependence of gating.

MOL 12278

Concentration effects were quantified by fitting the data to the Hill equation ($I_{\text{drug}}/I_{\text{control}}=1/[1+(D/IC_{50})^H]$), where D is the drug concentration, IC_{50} is the drug concentration for 50% block, and H is the Hill coefficient to the results. Data are given as mean \pm standard error of the mean (SEM). Clampfit (Axon Instruments) and Origin (Microcal Software) were used for data analysis. Curve fitting was done using multiple non-linear least squares regression analysis. All experiments were performed at room temperature ($23\pm 1^\circ\text{C}$).

RESULTS

External K⁺ and inactivation gating regulate cisapride block of HERG channels

Consistent with previous studies (Mohammad *et al.*, 1997; Mitcheson *et al.*, 2000a; Chen *et al.*, 2002), we found that cisapride potently blocks HERG channels in a stably transfected HEK 293 cell line. Fig. 1A and B show families of current traces from one cell for control conditions (Fig. 1A) and after exposure to 100 nM cisapride (Fig. 1B). Fig. 1C shows the current-voltage (I-V) relationships of the pulse currents measured at the end of depolarizing steps and the peak tail current before and after exposure to 100 nM cisapride. 100 nM cisapride markedly reduced the pulse and tail currents.

Changes in extracellular K⁺ concentration (K⁺_o) have been shown to influence the binding of drugs such as dofetilide and E-4031 to I_{Kr}/HERG channels (Yang and Roden, 1996; Wang *et al.*, 1997). We found that the potency of cisapride block of the WT HERG channel was also strongly modulated by K⁺_o as demonstrated in Fig. 1D and E. Fig. 1D shows the superimposed currents before and after exposure to 50 nM cisapride in bath solutions containing 0, 5 or 135 mM K⁺ with a pipette solution containing 135 mM K⁺. From a holding potential of -80 mV, HERG currents were evoked by a depolarization to 50 mV for 4 s, followed by a step to -50 mV to record tail current. Since it is reported that cisapride binds to HERG only after the channel opens (Mohammad *et al.*, 1997), a series of depolarizing pulses was delivered every 15 s until a steady-state block was reached. The blocking effects were measured by the degree of peak tail current suppressions. The cisapride block of HERG is strongly K⁺_o dependent. As can be seen in Fig. 1D, 50 nM cisapride blocked ~80% of the current in the absence of K⁺_o, ~60% at 5 mM K⁺_o, ~20% at 135 mM K⁺_o. To obtain a concentration-dependent relationship for block of HERG current by cisapride, 6 to 8 cells

MOL 12278

were studied at each drug concentration. Under each K^+_o condition, the tail current peak amplitude was normalized to the respective control value and was plotted as relative current amplitude against cisapride concentration (Fig. 1E). Data points were fitted to the Hill equation. The half-maximal inhibition concentration (IC_{50}) for cisapride block of HERG current was 7.5 ± 0.8 nM at 0 K^+_o , 24.1 ± 1.2 nM at 5 mM K^+_o , and 108.8 ± 12.9 nM at 135 mM K^+_o . The IC_{50} values are significantly different from one another ($n=6-8$ cells for each data point, $p<0.01$). The corresponding Hill coefficients were 0.8, 1.0 and 1.0, respectively, suggesting that the occupation of a single binding site accounts for the block by cisapride.

Since K^+_o regulates HERG inactivation, and inactivation has been shown to play an important role in high affinity drug binding to HERG channels (Zhang *et al.*, 1999; Zhang *et al.*, 2003a), we assessed the role of HERG inactivation in altering cisapride block at different K^+_o . We constructed an inactivation deficient mutant HERG channel, S620T (Fig. 2). The S620T mutation lies in the S5-S6 linker of the channel pore. Previous studies have shown that this mutation interferes with the C-type inactivation and modifies the blocking of HERG channels caused by dofetilide, clofilium and verapamil (Ficker *et al.*, 1998; Suessbrich *et al.*, 1997; Zhang *et al.*, 1999). Consistent with these previous reports, we found that the conservative substitution of serine with threonine at position 620 resulted in a complete removal of inactivation. Fig. 2A and B show families of the S620T currents from one cell for control conditions (Fig. 2A) and after exposure to cisapride (Fig. 2B). The cell was clamped at a holding potential of -80 mV. Depolarizing steps were applied for 4 s to voltages between -70 and +70 mV in 10-mV increments. For control conditions, depolarizing steps activated a time-dependent outward current that increased in amplitude as voltage steps became more positive. The inward rectification seen in WT HERG channels was absent (Fig. 2C). In the

MOL 12278

presence of 100 nM cisapride the S620T current displayed a time dependent decay during the depolarizing steps (Fig. 2B). Cisapride has been shown to preferentially block activated (open) channels (Mohammad *et al.*, 1997). Therefore, the decay reflects time dependent drug binding to open channels. Since release of cisapride block occurs during the resting potential, the time dependent block could be observed upon each depolarization (Mohammad *et al.*, 1997; Zhang *et al.*, 1999). Fig. 2C shows the I-V relationship of currents measured at the end of depolarizing steps in control and in the presence of 100 nM cisapride.

The cisapride block of HERG S620T channels and its K^+_o dependence were studied in Fig. 2D and E. HERG channels were activated by a depolarizing pulse to +50 mV for 4 seconds every 15 seconds. There was no clear sign of inactivation in control recordings. Unlike WT channels, the S620T mutant channel was blocked by cisapride in a K^+_o -independent manner. The steady-state block measured at the end of a 4 s depolarizing step under each cisapride concentration was normalized to its control value. Four to seven cells were studied at each concentration and the blocking effects were plotted against cisapride concentrations. The data were fitted to the Hill equation. The IC_{50} for cisapride at K^+_o of 0, 5, or 135 mM was 49.5 ± 2.1 , 77.5 ± 6.0 and 87.7 ± 11.5 nM, respectively (n = 4-7 cells). The Hill coefficients for the fits were 1.0, 1.2 and 1.0 at 0, 5 or 135 mM K^+_o , respectively.

Two observations are obvious. First, the S620T mutation reduced the sensitivity of the HERG channel to cisapride. For example, at K^+_o of 0, the IC_{50} of cisapride block of S620T was 49.5 nM, which is significantly higher than the IC_{50} (7.5 nM) for the WT channels ($P < 0.01$). Second, compared to WT channels the K^+_o dependence of cisapride block was significantly diminished in

MOL 12278

the S620T mutant channel. For example, whereas changing K^+_o from 135 mM to 0 increased cisapride block in the WT channel by 14.5 fold, the same decrease in K^+_o only increased cisapride block of the S620T channel 1.8 fold ($p < 0.01$). These results indicate that the K^+_o dependence of cisapride block of the WT HERG channel is largely related to the ability of K^+_o to slow HERG inactivation gating.

Cisapride block of HERG Cs^+ current is independent of inactivation gating

We have found that HERG channels display a unique high permeability to Cs^+ (Zhang *et al.*, 2003a). Since cisapride blocks HERG by binding to the internal cavity of the channel (Mitcheson *et al.*, 2000a), we hypothesized that intracellular K^+ (K^+_i) may play a role in drug binding to the HERG channel. We reasoned that intracellular Cs^+ (Cs^+_i) may differ from K^+_i in regulating the drug-HERG interactions, and we investigated the effects of cisapride on the HERG Cs^+ current. A pipette solution containing 135 mM Cs^+ and a bath solution containing various Cs^+ concentrations (Na^+ as substitute) were used to study the effects of extracellular Cs^+ on cisapride block. The WT HERG Cs^+ currents display very similar features to K^+ currents except there is a larger outward current peak upon depolarization which decays quickly as channels inactivate (see Fig. 5 A for the current voltage relationships of Cs^+ current). Cisapride blocked HERG Cs^+ current in a concentration dependent manner. However, as shown in Fig. 3, in contrast to that of the K^+ current, cisapride block of HERG Cs^+ current was entirely independent of extracellular Cs^+ concentration (Cs^+_o) which has been shown to slow HERG inactivation gating (Zhang *et al.*, 2003a). The IC_{50} for cisapride at Cs^+_o of 0, 5 or 135 mM was 173.6 ± 12.6 , 191.5 ± 9.4 and 195.6 ± 20.6 nM, respectively ($n = 4-7$ cells). The corresponding Hill coefficients were 1.3, 0.9 and 1.0, suggesting that the occupation of a single binding site accounts for the block of HERG Cs^+ current by cisapride.

MOL 12278

To address the effect of Cs^+_o on the inactivation time course of the Cs^+ current, HERG Cs^+ current was fully activated and inactivated by a depolarizing step to +40 mV for 500 ms. The cell was then repolarized to -100 mV for 10 ms to allow recovery from inactivation but not enough to allow significant deactivation of the HERG channels (Smith *et al.*, 1996; Spector *et al.*, 1996; Zhang *et al.*, 2003a). A test step was then applied to different voltages to observe inactivation time courses every 15 seconds. The inactivation time constant (τ_{inact}) was obtained by fitting the current decay to a single exponential function. Data in Fig. 4 A-C show HERG Cs^+ currents during the test steps to voltages between +20 and 120 mV in 20 mV increments at 0 (A), 5 (B) or 135 mM Cs^+_o (C). The expanded traces during the test pulses are shown in Fig. 4D-F. The averaged τ_{inact} in 0 (○), 5 (●) and 135 mM Cs^+_o (▲) in five to eight cells are plotted as a function of test potential in Fig. 4G. Elevated Cs^+_o slowed HERG Cs^+ current inactivation at all voltages tested. For example, τ_{inact} at 60 mV increased from 6.7 ± 0.9 ms in the absence of Cs^+_o ($n = 8$) to 23.2 ± 5.7 ms at 5 mM Cs^+_o ($n = 7$, $p < 0.01$), and to 198.7 ± 23.6 ms at 135 mM Cs^+_o ($n = 5$, $p < 0.01$). Thus, elevation of Cs^+_o markedly slowed HERG inactivation. The effects of Cs^+_o on the voltage dependence of steady-state inactivation were also studied. To construct the steady-state inactivation, ratios of the current measured 100 ms after the onset of inactivation relative to instantaneous peak current at each test potential were calculated. The ratios were normalized to the maximal value, plotted as a function of the test voltage and fitted to a Boltzmann function (Fig. 4H). Data were obtained from five to eight cells. The half-inactivation voltage and slope factor were -7.9 ± 0.7 mV and 16.2 ± 0.7 mV at zero Cs^+_o , 5.6 ± 0.6 mV and 16.7 ± 0.6 mV at 5 mM Cs^+_o , and 24.7 ± 1.2 mV and 15.1 ± 1.3 mV at 135 mM Cs^+_o , respectively. Elevation of Cs^+_o significantly shifted the mid-point of the steady-state inactivation curve to more depolarized potentials ($p < 0.01$) without significantly affecting the slope

MOL 12278

factor ($p > 0.05$). These results demonstrated that changing Cs^+ significantly slowed HERG inactivation but did not affect cisapride block of the Cs^+ current. Therefore, cisapride block and inactivation gating was not coupled in HERG Cs^+ current recordings.

To further evaluate the role of inactivation in the cisapride block of the HERG Cs^+ current, effects of cisapride on the WT and S620T Cs^+ currents were compared (Fig. 5). The pipette solution contained 135 mM Cs^+ and the bath solution contained zero Cs^+ (Na^+ ions as substitute). To record current-voltage relationships, HERG Cs^+ current was elicited by depolarizing steps to voltages between -70 and 70 mV for 4 seconds followed by a repolarizing step to -50 mV (Fig. 5A & B, upper panels). The holding potential was -80 mV. Fig. 5A shows the data from WT channels. The upper left panel shows a family of WT HERG Cs^+ currents in control, and the upper right panel shows the currents in the presence of 1 μ M cisapride. HERG Cs^+ currents were measured at the end of depolarizing steps to construct the I-V relationship (the lower panel of Figure 5A, $n = 6$ cells). In control conditions, the HERG current was activated at voltages positive to -50 mV, and a maximum current was reached at -10 mV. With more positive voltages the inward rectification was apparent due to the voltage-dependent rapid inactivation. 1 μ M Cisapride nearly completely blocked the HERG Cs^+ current. Fig. 5B shows the recordings from the inactivation-deficient mutant channel S620T. The upper left panel shows a family of S620T HERG Cs^+ currents in control. The upper right panel shows the currents in the presence of 1 μ M cisapride. The S620T Cs^+ current was measured at the end of 4 s depolarizing steps to construct the I-V relationship (the lower panel of Fig. 5B, $n = 4$ cells). The inactivation of Cs^+ current has been largely removed by the S620T mutation. The S620T Cs^+ current was activated at voltages positive to -40 mV. In contrast to the WT channel, the amplitudes of the S620T currents at the end of 4 s depolarizing pulse became

MOL 12278

larger as the depolarization was more positive. The inward rectification was absent. However, similar to the WT channel, 1 μM cisapride almost completely blocked the S620T Cs^+ current. To quantify the potency of cisapride block of HERG current, the concentration-dependent relationships were constructed with four to six cells studied at each drug concentration. For WT channels, HERG channels were activated and inactivated by a depolarization to 50 mV, the peak tail current upon repolarization to -50 mV was recorded to measure the channel block. For S620T channels, block was measured by current amplitudes at the end of a depolarizing step to 50 mV. The current amplitudes in the presence of cisapride were normalized to the control and plotted against cisapride concentration (Fig. 5C). Data points were fitted to the Hill equation. The IC_{50} for the WT and S620T channels were 173.6 ± 12.6 nM ($n = 6$) and 194.9 ± 19.6 nM ($n = 4$) with a Hill coefficient of 1.3 and 0.9, respectively. These concentration-dependent relationships were similar. Thus, in contrast to the K^+ current, the blocking of the HERG Cs^+ current by cisapride is independent of the inactivation gating.

Phe-656 of HERG is involved in the inactivation-facilitated cisapride block of K^+ current

Our results thus far have demonstrated that when K^+_i is replaced by Cs^+_i , cisapride block of HERG is no longer affected by HERG inactivation gating. This indicates a critical role of K^+_i in the state-dependence of cisapride binding to HERG channels. Phe-656 has been shown to be critical for cisapride binding to HERG channels (Mitcheson *et al.*, 2000a). We hypothesized that the positioning of Phe-656 may differ between open and inactivated state, and this may affect the binding of cisapride to HERG channels. The positioning of Phe-656 may be influenced by the types of the permeating ions. Therefore, K^+ and Cs^+ will result in different Phe positioning, ultimately affecting cisapride binding. When Cs^+ is permeating the channel, the optimal positioning of Phe-

MOL 12278

656 for cisapride binding may be less favored. To test the role of Phe-656 in the inactivation-induced changes of drug affinity, we mutated phenylalanine at 656 to valine or methionine. Fig. 6 shows the activation properties of the HERG F656V (A-C) and F656M (D-F). The currents were recorded in 135 mM K^+_i and 5 mM K^+_o by 4 s depolarizing steps to voltages between -70 and 70 mV. The holding potential was -80 mV. Fig 6B shows the I-V relationship of the F656V pulse currents. The outward currents measured at the end of 4 s depolarizing pulses were plotted against depolarizing voltages. The HERG F656V current was activated at voltages positive to -50 mV, and the maximum current was reached at 0 mV. At more positive voltages inward rectification was apparent due to the rapid voltage-dependent inactivation (Smith *et al.*, 1996; Spector *et al.*, 1996; Zhang *et al.*, 1999). Fig. 6C shows the activation curve for the F656V channel. Tail current amplitude was used to construct the activation curve ($n = 5$ cells), which shows that the threshold voltage for the F656V channel activation was close to -40 mV. The channels were fully activated at voltages > 20 mV. When fitted to a Boltzmann function, the half-maximum activation voltage ($V_{1/2}$) and slope factor (k) were -10.1 ± 2.7 mV and 8.7 ± 0.6 , respectively. These values are not significantly different from those in WT channels ($V_{1/2}$: -11.1 ± 4.0 mV k : 7.9 ± 0.7 mV). To assess deactivation of the F656V channel, the decay of tail currents at -50 mV were fitted to double exponential functions. The fast and slow components of deactivation time constants (τ_{deact}) at -50 mV were 186.1 ± 13.4 and 723.9 ± 42.3 ms ($n=5$). The fast component accounted for 0.59 of the current amplitude. For WT channels, the fast and slow components of τ_{deact} at -50 mV were 370.5 ± 18.9 and 1762.2 ± 156.5 ms ($n=6$). The fast component accounted for 0.47 of the current amplitude. Therefore, the F656V channel displayed a significantly faster deactivation than the WT channel ($n=5$ or 6, $p<0.01$).

MOL 12278

Fig. 6E and F show the I-V relationship (E) and the activation curve of F656M (F). The $V_{1/2}$ and slope factor were -17.1 ± 3.7 mV and 7.2 ± 0.4 , respectively ($n = 5$). While the $V_{1/2}$ of F656M displayed a moderate but significant shift to the negative potentials ($p < 0.05$), the slope factor of F656M was not different from that of WT channels. The deactivation time course of F656M was evaluated at -50 mV. The fast and slow components of τ_{deact} at -50 mV were 385.4 ± 45.1 and 2092.4 ± 190.8 ms ($n=5$). The fast component accounted for 0.42 of the current amplitude. These values were not significantly different from those of WT channels.

Fig. 7 compares the inactivation properties of WT channels (A), F656V (B) and F656M mutant channels (C). Panels *a* show the voltage dependence of the inactivation time course of K^+ currents from WT, F656V and F656M at 5 mM K^+_o . The inactivation time constant (τ_{inact}) was obtained by fitting the currents to a single exponential function at each test voltage. The averaged τ_{inact} in 0, 5 and 135 mM K^+_o ($n = 6-8$ cells) are plotted against test potentials in panels *b*. While there was no significant difference in the τ_{inact} between WT and the F656V channel, the τ_{inact} were significantly smaller for the F656M channel. For example, the mean time constants at 20 mV in the absence of K^+_o were 9.2 ± 0.9 ms, 7.4 ± 1.2 ms and 6.3 ± 0.4 ms for WT, the F656V and the F656M, respectively ($n = 5\sim 6$ cell each, $p > 0.05$ between WT and the F656V, and $p < 0.05$ between WT and the F656M). Despite of the small difference of τ_{inact} between WT and the F656M channel, elevation of external K^+ caused a similar slowing of the inactivation time course in the WT, F656V and F656M channels. Panels *c* show the steady-state inactivation relationships at different K^+_o of WT, the F656V and F656M channels. The data were fitted to a Boltzmann function. The half-inactivation voltage ($V_{1/2}$) and slope factor (k) were summarized in Table 2. While the inactivation properties of F656V were similar to those of WT channels, the $V_{1/2}$ for the F656M was significantly

MOL 12278

more negative than that of WT (n=5, p<0.01). However, despite of a moderately accelerated inactivation for the F656M channel, elevation of K^+_o caused a similar shift of the steady-state inactivation in the WT, F656V and F656M channels to the depolarized direction without significantly affecting the slope factors.

Consistent with the Phe-656 being a critical site for drug binding, both F656V and F656M affected cisapride binding to the channel (Fig. 8). While the F656V mutation significant reduced cisapride affinity, the F656M had only a modest effect. Significantly, we found that cisapride block of both F656V and F656M channels was not affected by changes of K^+_o which modulate inactivation gating of both channels (see Fig. 7). The IC_{50} for cisapride block of F656V at 0, 5, or 135 mM K^+_o was 99.9 ± 7.5 nM, 101.1 ± 5.7 nM, and 134.3 ± 13.2 nM, respectively (p>0.05, n = 4-7 cells). The corresponding Hill coefficients were 1.2, 1.3 and 1.0, respectively. The IC_{50} for cisapride block of F656M at 0, 5, or 135 mM K^+_o was 27.6 ± 2.1 nM, 30.6 ± 4.1 nM, and 34.0 ± 2.8 nM, respectively (p>0.05, n = 4). The corresponding Hill coefficients were 1.3, 1.3 and 0.9.

MOL 12278

DISCUSSION

The exact role of inactivation in mediating drug block of HERG is not well understood. In the present study, we found that cisapride block of HERG was significantly attenuated by the impairment of inactivation gating. First, elevation of K^+_o , which slows inactivation, reduced the degree of cisapride block. Second, the inactivation deficient mutant S620T had a reduced cisapride affinity. Site-directed mutagenesis has identified aromatic residues, particularly Phe-656 in the S6 transmembrane domain of HERG subunits, to be one of the most important molecular determinants of high affinity binding to HERG channels for many drugs such as MK-499, dofetilide, cisapride, terfenadine, quinidine, and chloroquine (Lees-Miller *et al.*, 2000; Mitcheson *et al.*, 2000a). To assess whether the facilitation of cisapride binding by inactivation gating is via the Phe-656 site, we evaluated the effects of K^+_o on cisapride block of F656V and F656M channels. We reasoned that if Phe-656 is involved in the inactivation-induced facilitation of cisapride binding to HERG channels, changing inactivation gating by K^+_o might differently affect the IC_{50} of HERG F656V and F656M. Indeed, we found that block of both mutant channels by cisapride was not affected by changing K^+_o , indicating that Phe-656 is involved in the inactivation-induced high affinity binding of cisapride to HERG channels. The loss of K^+_o regulation of cisapride-mediated block of F656V and F656M channels does not result from the altered drug sensitivity of the mutant channels. In our study, the F656V HERG mutation displayed reduced cisapride sensitivity, but the F656M mutant channel displayed similar cisapride sensitivity to that of WT channels at 5 mM K^+_o . The difference of the cisapride affinity between the F656V and F656M seems to be related to the measures of hydrophobicity at the position 656. Recently, it has been found that the potency for block of HERG by cisapride, terfenadine, and MK-499 correlate well with measures of hydrophobicity, especially the two-dimensional approximation of the van der Waals hydrophobic surface area of the side chain

MOL 12278

of residue 656 (Fernandez *et al.*, 2004). The van der Waals hydrophobic surface area of methionine more closely resembles that of phenylalanine than does the hydrophobic surface area of valine (Fernandez *et al.*, 2004). However, although the methionine residue mimics more closely the phenylalanine residue in regard to the hydrophobicity, both methionine and valine lack the aromatic ring of phenylalanine which may be important for the inactivation-facilitated cisapride binding to the channel. Based on the crystal structure of the KcsA K⁺ channel (Doyle *et al.*, 1998), Phe-656 of HERG (Thr-107 in KcsA) faces the central cavity of the intracellular mouth of the channel. The presence of a phenylalanine at this site in HERG appears to be important in creating a binding site for dofetilide, quinidine, MK-499, terfenadine and cisapride (Lees-Miller *et al.*, 2000; Mitcheson *et al.*, 2000a). These compounds consist of an aliphatic chain with benzene rings at each end. Benzene rings are known to stack via π bonds and it is possible that the benzene head groups of cisapride could interact with the benzene ring of phenylalanine. Because of the structural nature, we propose that the positioning of the benzene ring of phenylalanine is more likely to be affected by the channels inactivation gating, which affects drug binding. On the other hand, the positioning of the methionine residue may be less likely to be affected by the inactivation gating. Therefore, although F656M displayed cisapride sensitivity which was similar to WT channels, it lost the K⁺_o dependence of the cisapride block.

The loss of K⁺_o regulation of cisapride-mediated block of F656V and F656M channels seems not due to the altered channel gating behaviors. The inactivation properties of F656V were similar to that of WT channels whereas the F656M displayed a slightly accelerated inactivation. Like WT channels, elevation of K⁺_o significantly slowed inactivation of both F656V and F656M mutant channels. We have found that the F656M mutation moderately shifted the activation curve to

MOL 12278

hyperpolarized potentials. This result is consistent with a previous report (Fernandez *et al.*, 2004). We also found that the activation properties of F656V were not altered, but deactivation of the F656V was significantly faster than WT channels. The finding of the accelerated deactivation of the F656V is consistent with the previous studies (Lees-Miller *et al.*, 2000; Fernandez *et al.*, 2004). It seems that the accelerated deactivation may not be the primary cause for the reduction in drug sensitivity for the F656V. It has been shown that the F656W mutation significantly altered the voltage dependence of activation/deactivation gating, but this mutation did not significantly alter the IC₅₀ values for the block by MK-499, cisapride and terfenadine (Fernandez *et al.*, 2004).

The present study also revealed that the intracellular K⁺ is involved in modulating cisapride binding during inactivation gating. We found that when intracellular K⁺ is replaced by Cs⁺, inactivation gating no longer affects the cisapride mediated block of HERG. With Cs⁺ ions in the pipette solution, the IC₅₀ of cisapride were similar between the WT and inactivation-deficient S620T channels. Although elevation of extracellular Cs⁺ concentration significantly slowed the Cs⁺ current inactivation of WT HERG channels, it did not alter the cisapride block of HERG Cs⁺ current. Furthermore, we observed that altering inactivation affects the IC₅₀ of cisapride block of HERG less than does the intracellular Cs⁺ replacement, and that Cs⁺ replacement further reduced the IC₅₀ of cisapride in the inactivation-deficient mutant channels. For example, whereas S620T inactivation deficient mutation reduced the cisapride affinity by 6.6-fold in a bath solution containing 135 mM Na⁺, under the same bath solution replacement of the intracellular K⁺ by Cs⁺ reduced the cisapride affinity of WT channels by 23-fold. Replacement of intracellular K⁺ by Cs⁺ also reduced the cisapride affinity of S620T inactivation-deficient channels by 4-fold (IC₅₀ from 49.5 nM to 194.9

MOL 12278

nM, Fig. 2 and Fig. 5) in a bath solution containing zero K^+ and Cs^+ (135 mM Na^+). These results argue against inactivation as being the sole primary determinant of drug block.

The mechanism by which Cs^+ replacement affects cisapride block is not known but may be related to the positioning of the drug binding site. C-type inactivation reflects a stabilized P-type inactivation and S5-S6 arrangements might be involved in this process to affect the selectivity filter and adjacent structures. On the other hand, the permeant ions may modify the selectivity filter and adjacent structure (Zhou and MacKinnon, 2004). The occupancy of the selectivity filter by particular permeant ions might stabilize a conformation of the S5-S6 arrangement. We propose that the S5-S6 is stabilized by K^+ ions to a molecular state/position in which inactivation gating can further induce a conformational change that increases cisapride affinity to the channel. In contrast to K^+ , Cs^+ stabilizes the S5-S6 in a different molecular state/position that inactivation gating cannot increase cisapride affinity to the channel. Thus, in addition to direct interactions or via changes in channel inactivation, K^+ ions are also critical for maintaining a proper conformation of the channel required for drug-channel interactions.

In summary, we have found that both intracellular K^+ and Phe-656 are required for inactivation-related high affinity cisapride binding to HERG. We propose that intracellular K^+ ions stabilize the HERG channel in a state in which inactivation can alter the receptor site of Phe-656 to a position that favors high affinity cisapride binding. Our findings suggest a possible explanation for how inactivation gating facilitates drug affinity to HERG channels. It has been shown that block of Na^+ or Ca^{2+} channels by many drugs is facilitated by channel inactivation. Whether intracellular K^+

MOL 12278

plays a role in the state dependent block of Na⁺ or Ca²⁺ channels by drugs (Hille, 1977; Hondeghem and Katzung, 1984) requires further investigation.

MOL 12278

Acknowledgments

We thank Dr. Craig January (The University of Wisconsin) for the stable HERG cell line (Zhou *et al.*, 1998) and Dr. Gail Robertson (The University of Wisconsin) for the HERG cDNA (Trudeau *et al.*, 1995).

Reference List

- Chen J, Seeböhm G and Sanguinetti M C (2002) Position of Aromatic Residues in the S6 Domain, Not Inactivation, Dictates Cisapride Sensitivity of HERG and Eag Potassium Channels. *Proc Natl Acad Sci U S A* **99**:12461-12466.
- Doyle DA, Cabral J M, Pfuetzner R A, Kuo A L, Gulbis J M, Cohen S L, Chait B T and MacKinnon R (1998) The Structure of the Potassium Channel: Molecular Basis of K⁺ Conduction and Selectivity. *Science* **280**:69-77.
- Fernandez D, Ghanta A, Kauffman G W and Sanguinetti M C (2004) Physicochemical Features of the HERG Channel Drug Binding Site. *J Biol Chem* **279**:10120-10127.
- Ficker E, Jarolimek W, Kiehn J, Baumann A and Brown A M (1998) Molecular Determinants of Dofetilide Block of HERG K⁺ Channels. *Circ Res* **82**:386-395.
- Hille, B. Local anesthetics: hydrophilic and hydrophobic pathways for the drug-receptor reaction. *Journal of General Physiology* 69, 497-515. 1977.
- Ho SN, Hunt H D, Horton R M, Pullen J K and Pease L R (1989) Site-Directed Mutagenesis by Overlap Extension Using the Polymerase Chain Reaction. *Gene* **77**:51-59.
- Hondeghem LM and Katzung B G (1984) Antiarrhythmic Agents: the Modulated Receptor Mechanism of Action of Sodium and Calcium Channel-Blocking Drugs. *Annu Rev Pharmacol Toxicol* **24**:387-423.
- Keating MT and Sanguinetti M C (2001) Molecular and Cellular Mechanisms of Cardiac Arrhythmias. *Cell* **104**:569-580.
- Kiehn J, Lacerda A E, Wible B and Brown A M (1996) Molecular Physiology and Pharmacology of HERG - Single- Channel Currents and Block by Dofetilide. *Circ* **94**:2572-2579.
- Lees-Miller JP, Duan Y, Teng G Q and Duff H J (2000) Molecular Determinant of High-Affinity Dofetilide Binding to HERG1 Expressed in Xenopus Oocytes: Involvement of S6 Sites. *Mol Pharmacol* **57**:367-374.
- Mitcheson JS, Chen J, Lin M, Culberson C and Sanguinetti M C (2000a) A Structural Basis for Drug-Induced Long QT Syndrome. *Proc Natl Acad Sci U S A* **97**:12329-12333.
- Mitcheson JS, Chen J and Sanguinetti M C (2000b) Trapping of a Methanesulfonanilide by Closure of the HERG Potassium Channel Activation Gate. *J Gen Physiol* **115**:229-240.
- Mohammad S, Zhou Z, Gong Q and January C T (1997) Blockage of the HERG Human Cardiac K⁺ Channel by the Gastrointestinal Prokinetic Agent Cisapride. *Am J Physiol* **273**:H2534-H2538.

MOL 12278

Roden DM, Lazzara R, Rosen M, Schwartz P J, Towbin J and Vincent G M (1996) Multiple Mechanisms in the Long-QT Syndrome. Current Knowledge, Gaps, and Future Directions. The SADS Foundation Task Force on LQTS. *Circ* **94**:1996-2012.

Sanguinetti MC, Jiang C, Curran M E and Keating M T (1995) A Mechanistic Link Between an Inherited and an Acquired Cardiac Arrhythmia: *HERG* Encodes the I_{Kr} Potassium Channel. *Cell* **81**:299-307.

Sanguinetti MC and Jurkiewicz N K (1990) Two Components of Delayed Rectifier K^+ Current. *J Gen Physiol* **96**:195-215.

Smith PL, Baukrowitz T and Yellen G (1996) The Inward Rectification Mechanism of the *HERG* Cardiac Potassium Channel. *Nature* **379**:833-836.

Snyders DJ and Chaudhary A (1996) High Affinity Open Channel Block by Dofetilide of *HERG* Expressed in a Human Cell Line. *Mol Pharmacol* **49**:949-955.

Spector PS, Curran M E, Zou A R and Sanguinetti M C (1996) Fast Inactivation Causes Rectification of the I_{Kr} Channel. *J Gen Physiol* **107**:611-619.

Suessbrich H, Schonherr R, Heinemann S H, Lang F and Busch A E (1997) Specific Block of Cloned Herg Channels by Clofilium and Its Tertiary Analog LY97241. *FEBS Lett* **414**:435-438.

Trudeau MC, Warmke J W, Ganetzky B and Robertson G A (1995) *HERG*, a Human Inward Rectifier in the Voltage-Gated Potassium Channel Family. *Science* **269**:92-95.

Trudeau MC, Warmke J W, Ganetzky B and Robertson G A (1996) *HERG* Sequence Correction. *Science* **272**:1087.

Wang S, Morales M J, Liu S, Strauss H C and Rasmusson R L (1997) Modulation of *HERG* Affinity for E-4031 by K^+ and C-Type Inactivation. *FEBS Lett* **417**:43-47.

Yang T and Roden D M (1996) Extracellular Potassium Modulation of Drug Block of I_{Kr} . Implications for Torsade De Pointes and Reverse Use-Dependence. *Circ* **93**:407-411.

Zhang S, Kehl S J and Fedida D (2003a) Modulation of Human Ether-a-Go-Go-Related K^+ (*HERG*) Channel Inactivation by Cs^+ and K^+ . *Journal of Physiology-London* **548**:691-702.

Zhang S, Kurata H T, Kehl S J and Fedida D (2003b) Rapid Induction of P/C-Type Inactivation Is the Mechanism for Acid-Induced K^+ Current Inhibition. *J Gen Physiol* **121**:215-225.

Zhang S, Rajamani S, Chen Y, Gong Q, Rong Y, Zhou Z, Ruoho A and January C T (2001) Cocaine Blocks *HERG*, but Not $KvLQT1+MinK$, Potassium Channels. *Mol Pharmacol* **59**:1069-1076.

Zhang S, Zhou Z, Gong Q, Makielski J C and January C T (1999) Mechanism of Block and Identification of the Verapamil Binding Domain to *HERG* Potassium Channels. *Circ Res* **84**:989-998.

MOL 12278

Zhou Y and MacKinnon R (2004) Ion Binding Affinity in the Cavity of the KcsA Potassium Channel. *Biochemistry* **43**:4978-4982.

Zhou Z, Gong Q, Ye B, Fan Z, Makielski J C, Robertson G A and January C T (1998) Properties of HERG Channels Stably Expressed in HEK 293 Cells Studied at Physiological Temperature. *Biophys J* **74**:230-241.

MOL 12278

Footnotes

This work was supported by CIHR grant 7774, grant from Heart and Stroke Foundation of Manitoba and Establishment grant from Manitoba Health Research Council to S.Z. S.Z. is a recipient of the New Investigator Award from the Heart and Stroke Foundation of Canada. J.T.W. is a recipient of the New Investigator Award from the Canadian Institute of Health Research.

Address correspondence to:

Shetuan Zhang, Institute of Cardiovascular Sciences, St. Boniface General Hospital Research Centre and Department of Physiology, Faculty of Medicine, University of Manitoba, 351 Tache Avenue, Winnipeg, Manitoba Canada R2H 2A6. E-mail: szhang@sbrc.ca

Dr. Jijin Lin's present address: The first affiliated hospital, Shantou University Medical College, Shantou 515041, China.

Abbreviations:

HERG, human *ether-a-go-go*-related gene; WT, wild type; τ , time constant; I-V, current-voltage; LQTS, long QT syndrome; HEK, human embryonic kidney; I_{Kr} , cardiac rapidly activating delayed rectifier K^+ current; K^+_i , intracellular potassium concentration; K^+_o , extracellular potassium concentration.

MOL 12278

LEGENDS FOR FIGURES

Fig. 1. Extracellular K^+ concentration (K^+_o) regulates the cisapride block of HERG K^+ currents. **A** and **B**: HERG currents recorded in the control condition (**A**) and after exposure to 100 nM cisapride (**B**). The pipette solution contained 135 mM K^+ and the bath solution contained 5 mM K^+ . Voltage protocol is shown in the inset of panel **B**. The inter-pulse interval was 15 seconds. **C**: Current-voltage plots of the pulse currents (\circ , \bullet) at the end of the 4 s depolarizing steps and the peak tail currents (\triangle , \blacktriangle) before (\circ , \triangle) and after exposure to 100 nM cisapride (\bullet , \blacktriangle). **D**: HERG K^+ currents recorded in the absence and presence of 50 nM cisapride at K^+_o of 0, 5, or 135 mM. The currents were elicited by repetitive depolarizing steps to +50 mV for 4 seconds followed by a repolarization to -50 mV to record the tail current. The holding potential was -80 mV. **E**: Concentration dependent block of HERG channels by cisapride at K^+_o of 0 (\bullet), 5 (\blacktriangle) or 135 mM (\blacktriangledown).

Fig. 2. The S620T mutation reduces cisapride block and eliminates the K^+_o dependence of the cisapride block of HERG channels. **A** and **B**: The HERG S620T currents recorded in the control condition (**A**) and after exposure to 100 nM cisapride (**B**). The pipette solution contained 135 mM K^+ and bath solution contained 5 mM K^+ . Voltage protocol was the same as shown in the inset of Fig. 1B. **C**: The current-voltage relationship of the pulse currents at the end of 4 s depolarizing steps before (\circ) and after exposure to 100 nM cisapride (\bullet). **D**: The HERG S620T currents for control and in the presence of 200 nM cisapride at K^+_o of 0, 5 or 135 mM. Currents were elicited by a depolarization to +50 mV for 4 s followed by a repolarization to -50 mV. At K^+_o of 135 mM, the repolarization to -50 mV was brief (200 ms). The holding potential was -80 mV. **E**: Concentration

MOL 12278

dependence of cisapride block of S620T channels. The current amplitude at the end of 4-s depolarization to 50 mV was normalized to the control, plotted against cisapride concentrations, and fitted to the Hill equation.

Fig. 3. Extracellular Cs^+ concentration (Cs^+_{o}) does not regulate cisapride block of HERG Cs^+ currents. Whole cell Cs^+ currents were recorded with a pipette solution containing 135 mM Cs^+ and bath solutions containing 0, 5 or 135 mM Cs^+ . **A:** Cs^+ current recorded in absence and presence of 200 nM cisapride at Cs^+_{o} of 0, 5, and 135 mM. The currents were elicited by depolarizations to +50 mV from a holding potential of -80 mV. The depolarization was followed by a repolarization to -50 mV to record the tail currents. **B:** Concentration-dependent block of HERG Cs^+ currents by cisapride. The tail current peak amplitudes at -50 mV were normalized to the control and plotted versus cisapride concentration. Fits to data points at 0 (●), 5 (▲) or 135 mM Cs^+_{o} (▼) to the Hill equation are shown.

Fig. 4. Effects of Cs^+_{o} on HERG Cs^+ current inactivation. HERG Cs^+ currents were elicited by the voltage protocol shown at the top of the figure. The pipette solution contained 135 mM Cs^+ and the external solutions contained 0 (A), 5 (B) or 135 mM Cs^+ (C). A 500 ms pulse to 40 mV to activate and inactivate HERG was followed by a 10 ms pulse to -100 mV to recover inactivated channels to open state. Test steps were then applied to voltages varying between 20 and 120 mV in 20 mV increments to record the time course of inactivation which have been expanded in D, E and F, respectively. The current decay at test voltages was fitted to a single exponential function to obtain the inactivation time constant (τ_{inact}). **G:** Voltage dependence of τ_{inact} in external solutions containing 0 (○), 5 (●) or 135 mM (▲) Cs^+_{o} . Each point is the mean \pm S.E.M. for five to eight

MOL 12278

cells. **H:** The steady-state inactivation of the Cs^+ current at 0 (\circ), 5 (\bullet) or 135 mM (\blacktriangle) Cs^+ . Elevation Cs^+ significantly slowed the inactivation time course and shifted the steady-state inactivation to the depolarized direction ($n = 5-8$ cells, $P < 0.01$).

Fig. 5. Block of the HERG Cs^+ current by cisapride is not dependent on inactivation. The Cs^+ currents from WT and S620T channels were recorded with a pipette solution containing 135 mM Cs^+ and a bath solution containing 140 mM NaCl. **A and B:** The Cs^+ currents recorded in absence and presence of 1 μM cisapride in the WT (**A**) and S620T HERG channels (**B**). The upper panels show families of currents. The current amplitudes at the end of each depolarizing pulse were normalized to the largest amplitude and plotted against each depolarization voltage to obtain normalized I-V relationships which are shown in the lower panels. **C:** Concentration dependence of cisapride block of HERG Cs^+ currents in the WT (\bullet) and S620T channels (\blacktriangle). Cisapride blocked the WT and S620T Cs^+ currents with a similar potency.

Fig. 6. Activation properties of the F656V and the F656M channel. **A:** A family of the F656V K^+ currents (135 mM K^+ and 5 mM K^+). **B:** I-V plot of the F656V currents measured at the end of depolarizing steps. **C:** Activation curve of the F656V constructed based on the tail currents. The activation curve was fitted to a Boltzmann relationship. **D:** A family of the F656M K^+ currents. **E:** I-V plot of the F656M currents measured at the end of depolarizing steps. **C:** Activation curve of the F656M channel.

Fig. 7. Effects of K^+ on the inactivation time constants in the WT, F656V and F656M channel. In panels **a**, a voltage protocol shown on the top of the panel was used to record the time

MOL 12278

courses of inactivation. The inactivation time constant (τ_{inact}) was obtained by fitting the current decay to a mono-exponential function. Panels **b**: The τ_{inact} -voltage relationships at 0, 5 and 135 mM K^+ . Panels **c**: Steady-state inactivation at 0, 5 and 135 mM K^+ . The half-inactivation voltage and slope factor were summarized in Table 2.

Fig. 8. Cisapride block of the F656V and F656M is not affected by K^+ . **A:** The F656V K^+ currents in the absence and presence of 200 nM cisapride. From a holding potential of -80 mV, the channels were repetitively activated by a depolarization to +50 mV for 4 seconds followed by a repolarization to -50 mV to record tail currents. The inter-pulse interval was 15 seconds. The pipette solution contained 135 mM K^+ and the bath solution contained 0, 5 or 135 mM K^+ . **B:** Concentration dependent block of F656V currents by cisapride at K^+ of 0 (\blacktriangle), 5 (\bullet) or 135 mM (\blacksquare). Tail current amplitudes in the presence of cisapride were normalized to the control and plotted versus cisapride concentration. The data were fitted to the Hill equation. **C:** The F656M K^+ currents in the absence and presence of 30 nM cisapride. **D:** Concentration dependent block of the F656M currents by cisapride at K^+ of 0 (\blacktriangle), 5 (\bullet) or 135 mM (\blacksquare).

MOL 12278

Table 1. Primers used for PCR reactions. Mutant nucleotides are underlined.

Primers		Sequence
Flanking Primers	F	CCACAATGTCACTGAGAAGGTCACCCAGG
	R	GCAGTGAGCGGTTTCAGGTGCAGGCAGATGTC
S620T Primers	F	CTACTTCACCTTCA <u>C</u> CAGCCTCACCAGTGTGGG
	R	CCCACACTGGTGAGGCTG <u>G</u> TGAAGGTGAAGTAG
F656V Primers	F	ATGTATGCTAGCATC <u>G</u> TCCGCAACGTGTCCGC
	R	GCCGACACGTTGCCGA <u>C</u> GATGCTAGCATAACAT
F656M Primers	F	ATGTATGCTAGCATC <u>A</u> T <u>G</u> GGCAACGTGTCCGC
	R	GCCGACACGTTGCC <u>C</u> A <u>T</u> GATGCTAGCATAACAT

MOL 12278

Table 2. The steady-state inactivation parameters of the WT, F656V and F656M channels at 0, 5 and 135 mM K^+_o .

	0 K^+_o			5 K^+_o			135 K^+_o		
	$V_{1/2}$	k	n	$V_{1/2}$	k	n	$V_{1/2}$	k	n
WT	-50.1 ± 2.2	20.1 ± 1.1	6	-29.4 ± 1.4	20.6 ± 0.4	7	-8.9 ± 1.8	19.2 ± 1.2	5
F656V	-54.2 ± 4.1	25.2 ± 1.5	4	-33.1 ± 3.1	22.1 ± 1.9	5	-9.7 ± 2.9	25.1 ± 2.7	5
F656M	$-62.9 \pm 2.9^*$	21.6 ± 1.2	4	$-41.4 \pm 1.6^*$	20.9 ± 1.8	6	$-19.1 \pm 2.6^*$	19.1 ± 2.1	4

$V_{1/2}$: voltage for half maximal inactivation; k : slope factor; n: number of cells tested. *, $p < 0.01$.

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6











Figure 7

A: WT



B: F656V



C: F656M




Figure 8

